Pharma CEO: Daraprim Price Hike is ‘Terribly Unfortunate’

Dr. Francois Nader was CEO of NPS Pharmaceuticals, and recently sold it to Shire Pharmaceuticals for $5.3B. He shares with Privcap his analysis on the Daraprim pricing controversy, in which a new owner of this drug vastly increased the price, causing many to wonder what the effects will be on the pharmaceutical industry.